A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

In this article, we are going to take a look at where Hillenbrand, Inc. (NYSE:HI) stands against other oversold small cap stocks to buy right now. Market experts believe that the rally in the ...

A paper published in Proceedings of the 37th Annual ACM Symposium on User Interface Software and Technology, by researchers in Carnegie Mellon University's Human-Computer Interaction Institute, ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.